A Study to Evaluate the Safety and Tolerability of EXN407
Status:
Recruiting
Trial end date:
2022-08-09
Target enrollment:
Participant gender:
Summary
This first in human (FIH), Phase Ib/II study of EXN407 is a randomised, double-masked,
vehicle-controlled, multiple dose, dose-escalating study to evaluate the safety and
tolerability of EXN407 in subjects with centre involved Diabetic Macular Oedema (DMO), with
Centre-subfield macular thickness (CMT) between 280-420 µm and Best corrected visual acuity
(BCVA) better than or equal to 69 ETDRS score (approximate Snellen equivalent 20/40 (6/12
letters) in the study eye, which is considered secondary to diabetes mellitus.
This study will provide a basis for further clinical development of EXN407 ophthalmic
solution.